Inovio Pharmaceuticals Inc
INO1.465USD
+0.035+2.43%
Market hours （ET）Quotes delayed by 15 min
53.72MMarket Cap
LossP/E TTM
More Details of Inovio Pharmaceuticals Inc Company
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.
Company Info
Ticker SymbolINO
Company nameInovio Pharmaceuticals Inc
IPO dateDec 08, 1998
CEODr. Jacqueline Elizabeth Shea, Ph.D.
Number of employees134
Security typeOrdinary Share
Fiscal year-endDec 08
Address660 W. Germantown Pike
CityPLYMOUTH MEETING
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code19462
Phone18584103134
Websitehttps://www.inovio.com/
Ticker SymbolINO
IPO dateDec 08, 1998
CEODr. Jacqueline Elizabeth Shea, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. David B. Weiner, Ph.D.
Dr. David B. Weiner, Ph.D.
Director
Director
86.62K
+2.57%
Dr. Jacqueline Elizabeth Shea, Ph.D.
Dr. Jacqueline Elizabeth Shea, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.69K
+28.22%
Dr. Laurent M. Humeau, Ph.D.
Dr. Laurent M. Humeau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
32.62K
+10.36%
Mr. Peter D. Kies
Mr. Peter D. Kies
Chief Financial Officer
Chief Financial Officer
30.63K
+7.76%
Mr. Simon X. Benito
Mr. Simon X. Benito
Independent Chairman of the Board
Independent Chairman of the Board
12.19K
+21.62%
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
10.51K
+25.97%
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
8.92K
+32.11%
Ms. Lota S. Zoth, CPA
Ms. Lota S. Zoth, CPA
Independent Director
Independent Director
8.73K
+33.04%
Mr. Jay P. Shepard
Mr. Jay P. Shepard
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Dr. Ann Calby Miller, M.D.
Dr. Ann Calby Miller, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. David B. Weiner, Ph.D.
Dr. David B. Weiner, Ph.D.
Director
Director
86.62K
+2.57%
Dr. Jacqueline Elizabeth Shea, Ph.D.
Dr. Jacqueline Elizabeth Shea, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.69K
+28.22%
Dr. Laurent M. Humeau, Ph.D.
Dr. Laurent M. Humeau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
32.62K
+10.36%
Mr. Peter D. Kies
Mr. Peter D. Kies
Chief Financial Officer
Chief Financial Officer
30.63K
+7.76%
Mr. Simon X. Benito
Mr. Simon X. Benito
Independent Chairman of the Board
Independent Chairman of the Board
12.19K
+21.62%
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
10.51K
+25.97%
Revenue Breakdown
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
United States
65.34K
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Jul 27
Updated: Sun, Jul 27
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Deep Track Capital LP
6.12%
BlackRock Institutional Trust Company, N.A.
4.22%
The Vanguard Group, Inc.
3.98%
BofA Global Research (US)
2.56%
Geode Capital Management, L.L.C.
1.66%
Other
81.45%
Shareholders
Shareholders
Proportion
Deep Track Capital LP
6.12%
BlackRock Institutional Trust Company, N.A.
4.22%
The Vanguard Group, Inc.
3.98%
BofA Global Research (US)
2.56%
Geode Capital Management, L.L.C.
1.66%
Other
81.45%
Shareholder Types
Shareholders
Proportion
Investment Advisor
10.80%
Hedge Fund
6.99%
Investment Advisor/Hedge Fund
5.77%
Research Firm
3.06%
Individual Investor
0.56%
Bank and Trust
0.30%
Venture Capital
0.13%
Pension Fund
0.02%
Other
72.36%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
302
14.08M
27.64%
-1.14M
2025Q1
358
13.94M
38.02%
-1.87M
2024Q4
376
13.66M
38.08%
+2.74M
2024Q3
379
8.99M
34.33%
-1.39M
2024Q2
391
8.36M
32.11%
+1.80M
2024Q1
412
4.61M
19.75%
-2.01M
2023Q4
431
4.68M
20.64%
-2.86M
2023Q3
449
5.16M
23.15%
-3.37M
2023Q2
462
6.56M
29.43%
-5.01M
2023Q1
491
10.80M
49.36%
-1.98M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Deep Track Capital LP
3.12M
6.12%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.15M
4.22%
+393.45K
+22.37%
Mar 31, 2025
The Vanguard Group, Inc.
2.03M
3.98%
+355.37K
+21.23%
Mar 31, 2025
BofA Global Research (US)
1.30M
2.56%
+664.00K
+103.59%
Mar 31, 2025
Geode Capital Management, L.L.C.
846.80K
1.66%
+218.30K
+34.73%
Mar 31, 2025
Stonepine Capital Management, LLC
518.33K
1.02%
-531.67K
-50.64%
Mar 31, 2025
State Street Global Advisors (US)
514.15K
1.01%
+9.84K
+1.95%
Mar 31, 2025
Northern Trust Investments, Inc.
461.70K
0.91%
+242.90K
+111.02%
Mar 31, 2025
Susquehanna International Group, LLP
194.37K
0.38%
+152.20K
+360.91%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.02%
Avantis US Small Cap Equity ETF
0.01%
iShares Russell 3000 ETF
0%
Invesco RAFI US 1500 Small-Mid ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Biotechnology ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
DFA Dimensional US Core Equity Market ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.02%
Avantis US Small Cap Equity ETF
Proportion0.01%
iShares Russell 3000 ETF
Proportion0%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Biotechnology ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
DFA Dimensional US Core Equity Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jan 23, 2024
Merger
12<1
Jan 23, 2024
Merger
12<1
Jan 23, 2024
Merger
12<1
Jan 23, 2024
Merger
12<1
Date
Type
Ratio
Jan 23, 2024
Merger
12<1
Jan 23, 2024
Merger
12<1
Jan 23, 2024
Merger
12<1
Jan 23, 2024
Merger
12<1
